These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38231045)

  • 1. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
    Robert N; Chen C; Kim S; Zhang Z; Aguilar KM; Wang Y; Li B; Gaffney M; Huang X; McRoy L
    Future Oncol; 2024 Apr; 20(12):761-780. PubMed ID: 38231045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
    DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
    Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
    Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Tomlin-Harris T; Brufsky A
    Future Oncol; 2024; 20(19):1299-1307. PubMed ID: 38517416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
    Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
    Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
    Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
    Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
    Future Oncol; 2024; 20(19):1309-1317. PubMed ID: 38536033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
    Dajsakdipon T; Susiriwatananont T; Wongkraisri C; Ithimakin S; Parinyanitikul N; Supavavej A; Dechaphunkul A; Sunpaweravong P; Neesanun S; Akewanlop C; Dejthevaporn T;
    BMC Cancer; 2024 Aug; 24(1):1018. PubMed ID: 39152401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
    Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
    Oncologist; 2023 Oct; 28(10):866-874. PubMed ID: 37487056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.
    Patt D; Liu X; Li B; McRoy L; Layman RM; Brufsky A
    Clin Breast Cancer; 2022 Aug; 22(6):601-610. PubMed ID: 35643624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast.
    Brufsky A; Gallagher C
    Target Oncol; 2023 May; 18(3):321-326. PubMed ID: 37148492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.
    Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
    Future Oncol; 2022 Jan; 18(3):349-362. PubMed ID: 34842454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
    Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
    Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
    Yoshinami T; Nagai SE; Hattori M; Okamura T; Watanabe K; Nakayama T; Masuda H; Tsuneizumi M; Takabatake D; Harao M; Yoshino H; Mori N; Yasojima H; Oshiro C; Iwase M; Yamaguchi M; Sangai T; Kosaka N; Tajima K; Masuda N
    Breast Cancer; 2024 Jul; 31(4):621-632. PubMed ID: 38642245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
    Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
    Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.
    Law JW; Mitra D; Kaplan HG; Alfred T; Brufsky AM; Emir B; McCracken H; Liu X; Broome RG; Zhang C; DiCristo C; Chen C
    Curr Oncol; 2022 Feb; 29(2):1047-1061. PubMed ID: 35200588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
    Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
    Cancer Treat Res Commun; 2022; 32():100573. PubMed ID: 35567914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
    Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
    Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
    Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
    Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.